がん化学療法剤単独使用で完全寛解を認めたけい部リンパ節転移がんの2例  [in Japanese] Two Cases of Lymphnodes Metastasis of Cancer showed Complete Remission after Treatments with New Antitumor Drug  [in Japanese]

Access this Article

Author(s)

Abstract

新しい制癌剤の開発はめざましいものがあるが, その治療効果を判定することは, 今日の診断技術をもつてしても, 必ずしも容易ではない. そこで, 表在性リンパ節腫瘍(転移性)に対して, 新抗癌剤を, 単独で使用し, 肉眼的にその臨床効果を検討した\<br>症例は2例で, いずれも転移性のリンパ節腫で, 1例は扁平上皮癌, 他の1例は腺癌であつた. 前者には, アクラシノマイシン-Aを用い, 後者にはUFTを用いた. いずれの症例の抗癌剤血中濃度も, 有効域内に少なくとも3時間は維持された. 6週間投与後に効果判定を行つたが, いずれの症例も当該腫瘍に対する効果は, 完全寛解であつた. これら2症例は, その後6ヵ月は全く再発なく経過した.<br>新抗癌剤の効果判定には, 肉眼的に判定し得る表在性の腫瘍が最適であり, これによつて, その臨床効果を推定し得ることを述べた.

Two cases with lymphnodes metastasis of cancer have been treated with new antitumor drugs, Aclacinomycin-A and Uracil-Futraful (UFT), respectively. Both cases have been revealed complete remission after several weeks of the treatments.<br>Aclacinomycin-A is a new type of anthracyclic antibiotics with different nature from those of daunomycin and adriamycin. Particularly, the side effects of Aclacinomycin-A is less pronounced than those of adriamycin and daunomycin.<br>On the other hand, UFT is a mixture of uracil and futraful in molar ratio of 4 : 1 According to the results of animal experiments UFT is believed that the uptake is extremely higher then that of f utraf ul alone, and in particular, the uptake of futraful to malignant titssues is so higher than that of the single administration of futraful that the concentration of 5 -FU is also high in plasma and as well as cancer tissues.<br>Therefore, it is expected through above basic results that both Aclacinomycin-A and UFT are expected to exhibit more effectiveness than that of adriamycin or daunomycin, and that of futraf ul. The results showed the complete remission in both cases. The side effects are less than any other antitumor drugs.

Journal

  • Japanese Journal of National Medical Services

    Japanese Journal of National Medical Services 34(6), 577-581, 1980

    Japanese Society of National Medical Services

Codes

  • NII Article ID (NAID)
    130004312772
  • NII NACSIS-CAT ID (NCID)
    AN00017113
  • Text Lang
    JPN
  • ISSN
    0021-1699
  • NDL Article ID
    2217208
  • NDL Source Classification
    ZS7(科学技術--医学)
  • NDL Call No.
    Z19-104
  • Data Source
    NDL  J-STAGE 
Page Top